Evidence that platelets from transfusion-dependent β-thalassemia patients induce T cell activation.


Journal

Clinical immunology (Orlando, Fla.)
ISSN: 1521-7035
Titre abrégé: Clin Immunol
Pays: United States
ID NLM: 100883537

Informations de publication

Date de publication:
08 2023
Historique:
received: 07 03 2023
revised: 21 05 2023
accepted: 24 05 2023
medline: 26 7 2023
pubmed: 4 6 2023
entrez: 3 6 2023
Statut: ppublish

Résumé

A hypercoagulable state leading to increased risk for thrombotic events represents one of the most common complications observed in transfusion-dependent β-thalassemia (TDT) patients. TDT patients have increased frequencies of circulating activated platelets. However, there is no information so far if platelets from TDT patients can activate T cells. In the present study we showed that T cells treated with platelets from TDT patients showed significant increased surface expression of CD69 compared to the T cells treated with platelets from healthy individuals. Patients with splenectomy showed increased T cell activation compared to patients with intact spleen. No T cell activation was observed following incubation with plasma alone, nor with platelets from healthy subjects. The percentages of regulatory T cells (Tregs) were also examined. TDT patients showed statistically significant increased percentages of Tregs compared to healthy controls. Additionally, we observed a positive statistically significant correlation between the percentages of Tregs and the platelet-induced activated T cells in patients who were not treated with aspirin. TDT patients showed increased levels of sP-selectin, suPAR and GDF-15, molecules implicated in platelet activation. We show that platelets from TDT patients can activate T cells in vitro. This activation correlates with markers of platelet activation and increased numbers of Tregs, perhaps in an effort to eliminate immune dysregulation, conceivably secondary to platelet activation.

Identifiants

pubmed: 37269985
pii: S1521-6616(23)00416-3
doi: 10.1016/j.clim.2023.109653
pii:
doi:

Substances chimiques

Aspirin R16CO5Y76E

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

109653

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.

Auteurs

Elena E Solomou (EE)

University of Patras Medical School, Department of Internal Medicine, Rio 26500, Greece. Electronic address: esolomou@upatras.gr.

Polyxeni Delaporta (P)

Division of Pediatric Hematology-Oncology, First Department of Pediatrics, Thalassemia Unit, National & Kapodistrian University of Athens, "Aghia Sophia" Children's Hospital, Full Member of ERN GENTURIS, Athens, Greece.

Aimilia Mantzou (A)

Division of Pediatric Hematology-Oncology, First Department of Pediatrics, Thalassemia Unit, National & Kapodistrian University of Athens, "Aghia Sophia" Children's Hospital, Full Member of ERN GENTURIS, Athens, Greece.

Marianna Tzannoudaki (M)

Department of Immunology-Histocompatibility, Specialized Center and Referral Center for Primary Immunodeficiencies-Pediatric Immunology, "Aghia Sophia" Children's Hospital, Athens, Greece.

Panagiotis Diamantopoulos (P)

First Department of Internal Medicine, National and Kapodistrian University of Athens, School of Medicine, Greece.

Christina Salamaliki (C)

University of Patras Medical School, Department of Internal Medicine, Rio 26500, Greece.

Christina-Nefeli Kontandreopoulou (CN)

First Department of Internal Medicine, National and Kapodistrian University of Athens, School of Medicine, Greece.

Nora-Athina Vyniou (NA)

First Department of Internal Medicine, National and Kapodistrian University of Athens, School of Medicine, Greece.

Foteini Perganti (F)

Division of Pediatric Hematology-Oncology, First Department of Pediatrics, Thalassemia Unit, National & Kapodistrian University of Athens, "Aghia Sophia" Children's Hospital, Full Member of ERN GENTURIS, Athens, Greece.

Ioannis Papassotiriou (I)

Division of Pediatric Hematology-Oncology, First Department of Pediatrics, Thalassemia Unit, National & Kapodistrian University of Athens, "Aghia Sophia" Children's Hospital, Full Member of ERN GENTURIS, Athens, Greece.

Antonis Kattamis (A)

Division of Pediatric Hematology-Oncology, First Department of Pediatrics, Thalassemia Unit, National & Kapodistrian University of Athens, "Aghia Sophia" Children's Hospital, Full Member of ERN GENTURIS, Athens, Greece.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH